Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M

ACADIA PHARMACEUTICALS INC

2025-Q2 EPS reported $0.27 revenue$508,882,000

Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).
Net income $26.7M ($0.16 EPS) vs $33.4M ($0.20 EPS) YoY due to higher tax rate.
Raised NUPLAZID net sales guidance low end to $665M; total revenue guidance $1.045-1.095B.
Patent litigation wins affirm NUPLAZID exclusivity through 2030 (composition) and 2038 (formulation).
COMPASS PWS Phase 3 study enrollment complete; top-line results expected early Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.